Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 1/20 | 0.58 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | RORB | Q92753 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940482 | 0.89 | HSD17B10 (0.48) | HNF4AFABP4ALDH1A1ALOX15MAPT | |
| SCHEMBL2832469 | 0.86 | BCAT2 (0.62) | HNF4ABCAT2TACR1MEN1KMT2A | |
| SCHEMBL27654634 | 0.86 | HNF4A (0.46) | HNF4AFABP4FABP3FABP5BCAT2 | |
| SCHEMBL2524408 | 0.86 | PTPN1 (0.46) | HNF4AFABP4FABP3FABP5BCAT2 | |
| SCHEMBL28334899 | 0.85 | DDT (0.54) | HNF4AFOLH1AKR1C2 | |
| SCHEMBL28498922 | 0.83 | HNF4A (0.44) | HNF4AFABP4FABP3FABP5BCAT2 | |
| SCHEMBL4700162 | 0.83 | HNF4A (0.44) | HNF4AFABP4FABP3FABP5BCAT2 | |
| SCHEMBL4188375 | 0.83 | BRS3 (0.45) | HNF4ATAS2R14 | |
| SCHEMBL544646 | 0.83 | ALDH1A1 (0.50) | HNF4AFABP4ALDH1A1ALOX15MAPT | |
| SCHEMBL28481844 | 0.82 | ALDH1A1 (0.52) | FABP4ALDH1A1ALOX15MAPTMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101820950-A | Biphenylcarboxamide derivatives as hedgehog pathway modulators | IRM LLC | 2010-09-01 | — | — | CN | claimed |
| CN-101218201-A | Benzoic acid derivatives as GlyR modulators or agonists | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | CN | claimed |
| CN-1938323-A | Silinane compounds as cysteine protease inhibitors | SCHERING AG (DE) | 2007-03-28 | — | — | CN | claimed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2025260159-A1 | ISOINDOLINE AND INDOLINE DERIVATIVE COMPOUNDS, COMBINATIONS, PHARMACEUTICAL COMPOSITIONS, MEDICAMENTS, USE OF THE COMPOUNDS AND METHOD OF TREATMENT OF PAIN | MICROBIOLÓGICA QUÍMICA E FARMACÊUTICA LTDA. (BR) | 2025-12-26 | — | — | WO | disclosed |
| CN-101820950-B | Biphenylcarboxamide derivatives as hedgehog pathway modulators | IRM LLC | 2015-01-21 | — | — | CN | disclosed |
| CN-102170873-B | Smoothied antagonism for treating disorders associated with HEDGEHOG pathways | NOVARTIS AG | 2014-07-30 | — | — | CN | disclosed |
| CN-103784457-A | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | NOVARTIS AG | 2014-05-14 | — | — | CN | disclosed |
| CN-102746285-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC | 2012-10-24 | — | — | CN | disclosed |
| EP-2346825-A2 | MODULATORS OF P2X3 RECEPTOR ACTIVITY | Evotec AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| CN-101820950-A | Biphenylcarboxamide derivatives as hedgehog pathway modulators | IRM LLC | 2010-09-01 | — | — | CN | disclosed |
| CN-101437800-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (BM) | 2009-05-20 | — | — | CN | disclosed |
| CN-101218201-A | Benzoic acid derivatives as GlyR modulators or agonists | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | CN | disclosed |
| CN-1938323-A | Silinane compounds as cysteine protease inhibitors | SCHERING AG (DE) | 2007-03-28 | — | — | CN | disclosed |
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2004-10-28 | — | — | US | disclosed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| CN-1240429-A | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID CO (US) | 2000-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | HNF4A 143/4885FABP4 364/4885FABP3 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.